NDTV-Dettol Banega Swasth Swachh India NDTV-Dettol Banega Swasth Swachh India
  • Home/
  • News/
  • With Start Of COVID Vaccination Around Corner, 70-80 Per Cent Reduction In COVAXIN Trial Participation: AIIMS Doctor


With Start Of COVID Vaccination Around Corner, 70-80 Per Cent Reduction In COVAXIN Trial Participation: AIIMS Doctor

Dr Sanjay Rai, Professor of Community Medicine at AIIMS said there is not as much excitement for clinical trial as over finalisation of a COVID-19 vaccine

With Start Of COVID Vaccination Around Corner, 70-80 Per Cent Reduction In COVAXIN Trial Participation: AIIMS Doctor
  • 1,500-2,000 participants are needed in phase 3 clinical trials of COVAXIN
  • AIIMS has been able to recruit only 200 participants for phase 3 trial
  • In phase 1, 2 trials of COVAXIN, a large volunteer participation was seen

New Delhi: With the start of COVID vaccination an immediate future in India, the phase III clinical trial for indigenously-developed Bharat Biotech’s vaccine candidate COVAXIN is witnessing a shortage of volunteer participation, with a high refusal rate 70 per cent to 80 per cent, a senior AIIMS doctor said on Wednesday (December 16). “When the clinical trial began, we wanted 100 volunteers and received over 4,500 applications. In phase II, we wanted 50 and received 4,000 applications. In phase III, now when wanted 1,500-2,000 participants, we could only recruit about 200 participants as of now. It is happening because people are thinking why to volunteer when a vaccine is coming for everyone soon,” Dr Sanjay Rai, Professor of Community Medicine at AIIMS told ANI.

Also Read: Bharat Biotech’s COVID-19 Vaccine Well Tolerated With No Serious Adverse Events: Phase 1 Trial Findings

Dr Rai said there is not much excitement for clinical trial as people are over-excited about the vaccine, and added that as per the guidelines of the Central government, in the first phase, vaccines will only be administered to priority groups.

Fact is that, even if a vaccine comes, it’ll be given to healthcare providers, frontline workers, elderly with co-morbidities first. But people think they will get vaccine soon, he added.

Also Read: Quarter Of World’s Population May Not Have Access To Coronavirus Vaccine Until 2022, Study Suggests

The government’s National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) recommended that prioritised population groups will specifically be vaccinated.

The group include–approximately one crore, healthcare workers (HCWs) healthcare providers and workers in the healthcare setting; about two crore frontline Workers (FLWs)which includes personnel from state and central police, armed forces, home guards, civil defence and disaster management volunteers, municipal workers; approximately 27 crores prioritized age group population above 50 years and persons below 50 years with associated co-morbidities.

This scenario was not seen in the phase I and phase II clinical trial. There was no refusal rate at all, Dr Rai who is a principal investigator for COVAXIN clinical trial said.

Dr Rai opined that because phase III is a double-blind clinical trial, the authorities have to inform the participants that 50 per cent would receive the vaccine and other 50 per cent would receive the placebo.

Also Read: States Receive Freezers, Ice-Lined Refrigerators For COVID-19 Vaccination: Ministry Of Health

After listening to this most of the participants refuse to participate in the clinical trial saying that vaccine is coming soon. Now we are planning to create awareness among people through advertisements, email and telephone. It is important for people to participate in the clinical trial to get a safe and efficient vaccine, he stated.

The doctor added that authorities are hoping to finish the phase III clinical trial by the end of this month (December).

Meanwhile, the Centre has prepared a detailed guideline for mass COVID vaccination. The Union Health Ministry has also directed the states to prepare for adverse events post COVID-19 vaccination as can’t be ruled out.

Till the time there is no vaccine, people have to strictly follow COVID-19 appropriate behaviour by wearing a face mask, washing or sanitising hands and maintaining social distancing.

Also Read: COVID-19 Vaccination Centre Issues Guidelines For Safe Waste Disposal Of Syringes

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This website follows the DNPA Code of Ethics

© Copyright NDTV Convergence Limited 2024. All rights reserved.